Overview of the stocks that were traded the most by DEGIRO clients in April 2021.

Most traded stocks by country: April 2021

April has historically been a strong month for the stock markets, and last month followed suit. The EURO STOXX 50 closed above 4,000 for the first time since the financial crisis of 2007-2008 and ended the month up by 1.42%. The S&P 500 climbed 5.24% in April also broke records, surpassing 4,000 for the first time.

In this article, we share the stocks that made an appearance on our map for the first time and the ones that saw the biggest price movements.

Out of the stocks on the map, Ocugen saw the biggest price increase during April.

Newcomers on the map

While we see some companies on the map month after month, four companies made their map debut, all of which are American companies:


Not only did Coinbase make its debut on our map, but it also made its debut on the stock market. On the 14th of April, Coinbase went public on the Nasdaq through a direct listing, a less traditional route compared to an initial public offering (IPO).

Coinbase is the largest US cryptocurrency exchange, and it made history being the first major crypto company to go public. Since the company went public through a direct listing, shares were not officially priced before they started trading. However, to help investors get an idea of the company’s value, a reference price of $250 was set on the 13th of April.

On its first day of trading, Coinbase had an opening price of $381. Prices climbed as high as $429.54 but ended the day at $328.28. At the end of April, shares were down by 21.88% from the opening price, closing at $297.64, giving the company a valuation of $59.29 billion.


Ocugen was traded the most by our Spanish, Italian and Swedish investors. It is a biopharmaceutical company based out of Pennsylvania that mainly focuses on developing therapies for eye diseases.

Ocugen is also involved in the development of a Covid-19 vaccine. At the end of 2020, Ocugen entered into a partnership with Indian drug maker Bharat Biotech to bring Bharat Biotech’s vaccine Covaxin to the US market. On the 21st of April, Bharat Biotech announced its second interim results of a late-stage study of its vaccine in India. The results indicated a 78% efficacy against Covid-19. At the end of April, stock prices were up by 86.60%.

Palantir Technologies

Another newcomer to the map was Palantir, a software company based in Colorado that specialises in big data analytics. It was traded the most by our Czech clients. The company was founded in 2003 and named after the magical ‘seeing stone’ in “Lord of the Rings.” With its three main products Gotham, Foundry and Apollo, Palantir serves a wide range of customers, including government agencies, financial firms, manufacturers and more.

At the beginning of April, Palantir announced that it was selected by the National Nuclear Security Administration (NNSA) to provide its security platform in a 5-year deal worth up to $89.9 million. This news, however, did not seem to have a positive impact on share prices as they decreased by 1.07% during the month.


Lastly, MicroVision made our map for the first time and was the most traded stock by our Danish and Norwegian clients. The company develops laser beam scanning technology and is headquartered in Washington.

MicroVision is one of the latest so-called meme stocks. On the 26th of April, MicroVision was the most mentioned stock on Reddit’s WallStreetBets forum, and prices jumped by 47.13%. However, prices plunged by 23.75% the following day.

MicroVision’s stock price fell further following its first-quarter 2021 results announcement on the 29th of April, reporting earnings-per-share (EPS) and sales figures that missed analysts’ estimates. Shares closed down by 17.79% at the end of the month.

Biggest movements

Out of the stocks on the map, Ocugen’s 86.60% increase made it April’s winner. On the losing end was small-cap French biotechnology company Novacyt, with prices decreasing by 37.61%. Novacyt specialises in clinical diagnostics and also manufactures Covid-19 test kits. On the 9th of April, the company announced that it had failed to extend its contract with the UK Department of Health and Social Care (DHSC). Following the announcement, share prices fell sharply by 38.41%.

Investing with DEGIRO

We want to make investing accessible to everyone by offering incredibly low fees. For details, please visit our Fees page.

On top of low fees, we offer you access to one of the largest universes of products and exchanges. This can help you influence your risk by building a well-diversified portfolio and spreading your investments over different types, regions and sectors. For an overview of the products and exchanges we offer, please visit our Markets page.

Open an account

The information in this article is not written for advisory purposes, nor does it intend to recommend any investments. Please be aware that facts may have changed since the article was originally written. Investing involves risks. You can lose (a part of) your deposit. We advise you to only invest in financial products that match your knowledge and experience.

Sources: Bloomberg, FX Street, Motley Fool, New York Times, Forbes, Coinbase, Ocugen, Palantir, MicroVision, The Street, Reuters


Get started with investing in 10 lessons

Investor's academy academy

Start investing today

Open a free account invest

Your investment journey starts here

Open a free account and join over 2.5 million investors worldwide on our user-friendly platform.

Investing involves risks. You can lose your invested funds. We advise you to only invest in financial products which match your knowledge and experience. This is not investment advice.

Investing places your capital at risk. Read our full warning here.


We want to empower people to become the best investors they can be. By offering a universe of possibilities and choices on our user-friendly platform, we are removing barriers to make investing accessible to everyone: beginners or experts. You get access to a wide variety of products on more than 50 global exchanges to have the freedom to invest the way you like. In our world, you also get great value for money. So, without compromising an inch on the quality, security and range of our investment services, we offer incredibly low fees. Prioritising your needs has helped us become the leading European online broker. Our 2.5+ million clients and 100+ international awards are proof of our success.

This communication is issued on behalf of flatexDEGIRO Bank AG and has been approved as a financial promotion on 3rd August 2023, for the purposes of section 21 of the Financial Services Market Act 2000 (FSMA), by Resolution Compliance Limited which is authorised and regulated by the Financial Conduct Authority (FRN:574048). flatexDEGIRO Bank AG is an overseas firm which is not authorised by the Financial Conduct Authority. This means that the FCA Rules made under FSMA for the protection of retail clients do not apply to the services provided by flatexDEGIRO Bank AG but investors are instead protected under applicable German law and Dutch law rules that apply to flatexDEGIRO Bank AG. Investors are not protected by the UK Financial Services Compensation Scheme.

flatexDEGIRO Bank Dutch Branch, a foreign branch of flatexDEGIRO Bank AG | Amstelplein 1, 1096HA Amsterdam | phone: +31 20 261 3072 | e-mail: clients@degiro.com | flatexDEGIRO Bank Dutch Branch is registered with the Dutch Chamber of Commerce under number 82510245. | flatexDEGIRO Bank Dutch Branch, trading under the name DEGIRO, is the Dutch branch of flatexDEGIRO Bank AG. flatexDEGIRO Bank AG is an overseas company primarily supervised by the German financial regulator (BaFin). In the Netherlands, flatexDEGIRO Bank Dutch Branch is registered with DNB and supervised by AFM and DNB. | flatexDEGIRO Bank AG is a licensed German bank supervised by the German financial regulator and registered with the German Chamber of Commerce under number HRB 105687.